DRI Capital is a private investment firm that seeks to acquire royalties from pharmaceutical and biotechnology companies, research institutions, universities, and inventors. DRI Capital’s focus is on products that treat chronic, critical and/or rare diseases and which improve the health and quality of a patient’s life. In addition to the traditional focus on pharmaceutical products, DRI Capital considers investments in royalty entitlements on medical devices, diagnostic products and life science tools and technologies. DRI Capital was established in 1992 and is headquartered in Toronto, Ontario.
Sectors of Interest: Healthcare Services, Life Science, Medical Products
Target Transaction Types: Buyout (LBO, MBO, MBI)
Geographic Preferences: East US, Midwest US, South US, West US, Canada
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.